Nucl Med Mol Imaging.  2020 Apr;54(2):114-119. 10.1007/s13139-020-00638-7.

First In-Human Medical Imaging with a PASylated 89Zr-LabeledAnti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer

Affiliations
  • 1Nuklearmedizinische Klinik und Poliklinik, Klinikumrechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675 Munich, Germany
  • 2Lehrstuhl für Biologische Chemie, Technische UniversitätMünchen, Emil-Erlenmeyer-Forum 5, 85354 Freising, Germany
  • 3Comparative Experimental Pathology, Institut für Allgemeine Pathologie und Pathologische Anatomie, Technische Universität München, 81675 Munich, Germany
  • 4Department of Gynaecology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
  • 5Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany

Abstract

Purpose
PASylation® offers the ability to systematically tune and optimize the pharmacokinetics of protein tracers for molecular imaging. Here we report the first clinical translation of a PASylated Fab fragment (89Zr∙Df-HER2-Fab-PAS200) for the molecular imaging of tumor-related HER2 expression.
Methods
A patient with HER2-positive metastatic breast cancer received 37 MBq of 89Zr∙Df-HER2-Fab-PAS200 at a total mass dose of 70 μg. PET/CT was carried out 6, 24, and 45 h after injection, followed by image analysis of biodistribution, normal organ uptake, and lesion targeting.
Results
Images show a biodistribution typical for protein tracers, characterized by a prominent blood pool 6 h p.i., which decreased over time. Lesions were detectable as early as 24 h p.i. 89Zr∙Df-HER2-Fab-PAS200 was tolerated well.
Conclusion
This study demonstrates that a PASylated Fab tracer shows appropriate blood clearance to allow sensitive visualization of small tumor lesions in a clinical setting.

Keyword

Breast cancer (BCa); Fab fragment; Human epidermal growth factor receptor 2 (HER2); Imaging; PASylation; 89Zr
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr